August 21-23, 2018

Boston, MA

Day One
Wednesday, August 22, 2018

Day Two
Thursday, August 23, 2018

Chairs Opening Remarks

  • Brian Berridge Associate Director, National Toxicology Program, Scientific Director , NIEHS

3D Models Guiding Indication Selection & Biomarker Discovery

Utilizing A 3D Tissue Platform from Bench to Bedside for Mechanistic Studies & Identifying Translational Biomarkers

Predicting Clinical Outcomes Through the Development 3D Assays on Tumor Biopsies

Morning Refreshments Networking

In Vitro Platforms Informing Early Stage Discovery Efforts

10.30 Interrogating Phenotypic Changes of 3D Neural Models to Discover & Validate Biomarker Candidates

Eric McDuggie, Scientific Director & Head of Investigative & Mechanistics Toxicology, Johnson & Johnson

Advancing Drug Metabolism and Pharmacokinetic Profiling

10.30 Key Criteria of Advanced 3D Human Liver Models for the Improvement of Safety Testing and Widespread Adoption

Andreas R. Baudy, Associate Principal Scientists, Safety Assessment, Merck & Co.